Kalaris Therapeutics shareholders elect Ferrara, Hallal, Patterson as Class III directors

Kalaris Therapeutics, Inc.

KLRS

0.00

Kalaris Therapeutics held its annual shareholder meeting on June 3, 2026.
Shareholders backed the board’s slate of Class III director nominees for three-year terms expiring at the 2029 annual meeting.
Investors voted to hold future advisory votes on executive pay every year; the board indicated it intends to follow that schedule.
Shareholders ratified Deloitte & Touche as independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalaris Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-257388), on June 04, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.